Development and Validation of Acceptance Questionnaire for The Use of Virtual Reality in Upper Limb Rehabilitation

September 27, 2026 updated by: Mahmoud Aboraya

Development and Validation of Acceptance Questionnaire for The Use of Virtual Reality in

The development of an Arabic questionnaire to assess acceptance of VR in upper limb rehabilitation would include adapting Technology Acceptance Model TAM, followed by panel review for content validity. Subsequently, a pilot testing with a sample of patients that would be followed by face validity testing then administering the revised instrument to a larger sample for comprehensive psychometric evaluation. Reliability would be established through internal consistency and test-retest parameters, while validity includes construct validation via factor analysis and criterion comparisons with related scales

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Recruiting
        • Cairo University, Faculty of physical therapy, virtual reality lab
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults receiving physical rehabilitation for upper limb pathology using virtual reality

Description

Inclusion Criteria:

  • Subjects age would range from 20 to 50 years old
  • Receiving VR rehabilitation for upper limb mobility (shoulder impingement, frozen shoulder or stroke).

Exclusion Criteria:

  • A medical implant or epilepsy will be grounds for exclusion based on the HMD-VR device's EU safety regulations.
  • Poor vision or hearing that can't be corrected by glasses or a hearing aid
  • inability to provide informed consent and previous HMD-VR exposure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: CROSS_SECTIONAL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Content validity index CVI (item level-level and scale-level)
Time Frame: During the first 2 months of the study or phase 1 which entails collecting opinions and assessments from VR rehab experts on the clarity and relevance of the questionnaire questions

Content validity index of each question of the initial draft would be calculated after giving the initial draft to a group of virtual reality experts to assess which of the questions would stay as is and which would be modified or deleted
During the first 2 months of the study or phase 1 which entails collecting opinions and assessments from VR rehab experts on the clarity and relevance of the questionnaire questions

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Internal consistency
Time Frame: During phase 2 which is 3rd and 4th month of the study, when the developed questionnaire would be piloted on a small group of participants 20-30

It would be used to would be used to determine whether questions in each factor measure the same underlying concept. Cronbach's alpha would be used <.7 would be considered acceptable.
During phase 2 which is 3rd and 4th month of the study, when the developed questionnaire would be piloted on a small group of participants 20-30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mahmoud Aboraya

Collaborators

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 12, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

September 20, 2026

First Submitted That Met QC Criteria

September 27, 2026

First Posted (Actual)

September 30, 2026

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 27, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • MAJUN26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe